首页> 外文OA文献 >Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis

【2h】

Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis

机译：达沙替尼（BMS-354825）抑制KITD816V，这是一种对伊马替尼具有抗性的激活突变，可触发大多数系统性肥大细胞增多症患者的肿瘤生长

页面导航

著录项
引文网络
相似文献

著录项

作者
Shah Neil P.; Lee Francis Y.; Luo Roger; Jiang Yibin; Donker Marjolein; Akin Cem;
展开▼
作者单位

展开▼
年度 2006
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis-associated clonal hematological nonmast cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F. [J] . Sotlar K, Bache A, Stellmacher F, The Journal of molecular diagnostics: JMD . 2008,第1期

机译：与慢性特发性骨髓纤维化相关的系统性肥大细胞增多症：系统性肥大细胞增多症相关的克隆性血液学非肥大细胞谱系疾病的一个独特亚型，携带激活点突变KITD816V和JAK2V617F。
2. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. [J] . Gleixner KV, Mayerhofer M, Cerny Reiterer S, Blood: The Journal of the American Society of Hematology . 2011,第7期

机译：系统性肥大细胞瘤中肿瘤细胞中不依赖KIT-D816V的致癌信号：达沙替尼和波舒替尼对Lyn和Btk激活和破坏的作用。
3. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates [J] . A Tefferi, R L Levine, K-H Lim, Leukemia . 2009,第5期

机译：系统性肥大细胞增多症中常见的TET2突变：临床，KITD816V和FIP1L1-PDGFRA相关
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Mutational analysis of the E5 protein of human papillomavirus type 16 to analyze the role of interaction with the 16-kDa subunit of the vacuolar H(+)-ATPase in inhibiting activity of this complex and altering metabolism of the epidermal growth factor receptor. [D] . Adam, Jamie L. 2000

机译：人类乳头瘤病毒16型E5蛋白的突变分析，以分析与液泡H（+）-ATPase的16-kDa亚基相互作用在抑制该复合物活性和改变表皮生长因子受体代谢中的作用。
6. Frequent TET2 mutations in systemic mastocytosis: clinical KITD816V and FIP1L1-PDGFRA correlates [O] . A Tefferi, RL Levine, K-H Lim, -1

机译：全身乳细胞症频繁的TET2突变：临床KITD816V和FIP1L1-PDGFRA相关
7. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis [O] . Shah Neil P., Lee Francis Y., Luo Roger, 2006

机译：达沙替尼（BMS-354825）抑制KITD816V，这是一种对伊马替尼具有抗性的激活突变，可触发大多数系统性肥大细胞增多症患者的肿瘤生长

Al论文写作

支持毕业 / 期刊论文写作

提供真实参考文献

超低查重率 / AIGC率

标准学术格式,含引用标注

可自定义写文大纲

毕业论文写作

期刊论文写作

Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis

著录项

引文网络

相似文献

相关主题

Al论文写作

期刊订阅